Premium
OUTCOMES OF PATIENTS POST IBRUTINIB TREATMENT FOR RELAPSED/REFRACTORY CLL: A UK AND IRELAND ANALYSIS
Author(s) -
Follows G.A.,
CLL Forum U.K.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_100
Subject(s) - ibrutinib , discontinuation , medicine , rituximab , venetoclax , refractory (planetary science) , idelalisib , pediatrics , oncology , leukemia , lymphoma , chronic lymphocytic leukemia , physics , astrobiology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom